The list included five new cancer therapies based on improved survival rates for lung, blood and prostate cancers, and recommended two new immunotherapies -- nivolumab and pembrolizumab -- that had improved survival rates by 50% for advanced melanoma, which was incurable until recently.
The list included five new cancer therapies based on improved survival rates for lung, blood and prostate cancers, and recommended two new immunotherapies -- nivolumab and pembrolizumab -- that had improved survival rates by 50% for advanced melanoma, which was incurable until recently.